Explore the latest updates and key analyses on companies, markets, and industry trends.
Entero Therapeutics, Inc. Announces Reverse Stock Split
Entero Therapeutics, Inc. (ENTO) | August 14, 2025
By Laura Young
Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split is to regain compliance with the Nasdaq listing requirements.
This move is aimed at enhancing shareholder value and maintaining the company's visibility and credibility.
Reverse Stock Split
1 for 3 reverse split to reduce outstanding shares and meet Nasdaq listing requirements.
Shareholder Impact
No fractional shares will be issued; shareholders entitled to cash for fractional shares.
CEO Statement
Richard Paolone, Interim CEO, emphasized the importance of the Nasdaq listing for shareholder value.
The reverse split will decrease outstanding shares from 4.77 million to 1.59 million.
Entero Therapeutics aims to strengthen its position in the market through improved visibility and credibility on the Nasdaq platform.
Entero Therapeutics' reverse stock split reflects a strategic move to enhance shareholder value and meet Nasdaq listing requirements, signaling long-term stability and commitment to growth.
